Brain tumor surgery that pushes boundaries boosts patients survival

Brain tumor surgery that pushes boundaries boosts patients survival

Press releases may be edited for formatting or style | February 07, 2020 Alzheimers/Neurology Operating Room
Survival may more than double for adults with glioblastoma, the most common and deadly type of brain tumor, if neurosurgeons remove the surrounding tissue as aggressively as they remove the cancerous core of the tumor.

This discovery, reported in a retrospective study headed by researchers at UC San Francisco, is welcome news for those in the glioblastoma community, which celebrated its last breakthrough in 2005 with the introduction of the chemotherapy drug temozolomide.

Removing the "non-contrast-enhancing tumor" -- so called because it does not light up on MRI when a contrast agent is injected into the vein -- represents a paradigm shift for neurosurgeons, according to senior author and neurosurgeon Mitchel Berger, MD, director of the UCSF Brain Tumor Center.

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

"Traditionally, the goal of neurosurgeons has been to achieve total resection, the complete removal of contrast-enhancing tumor," said Berger, who is also affiliated with the UCSF Weill Institute for Neurosciences. "This study shows that we have to recalibrate the way we have been doing things and, when safe, include non-contrast-enhancing tumor to achieve maximal resection."

Mutant Tumor Type Indicative of Longer Life

Some 22,850 Americans are diagnosed each year with glioblastoma -- one of the most relentless adult cancers and one that may be best known for claiming the lives of senators John McCain and Edward Kennedy, and the son of Vice President Joe Biden. The average survival for the 91 percent of glioblastoma patients whose tumor is characterized by IDH-wild-type mutations is 1.2 years, according to a 2019 study. However, the remaining 9 percent have a type of glioblastoma classified as IDH mutant, with average survival of 3.6 years.

In their study, which publishes in JAMA Oncology on Feb. 6, 2020, the researchers tracked the outcomes of 761 newly diagnosed patients at UCSF who had been treated from 1997 through 2017. The patients, whose average age was 60, were divided into four groups with varying risk based on age, treatment protocols, and extent of resections of both contrast-enhancing and non-contrast-enhancing tumor.

They identified a group of 62 patients whose average survival was 37.3 months (3.1 years). These patients had IDH-mutant tumors, or were under 65 with IDH-wild-type tumors and had undergone both radiation and chemotherapy with temozolomide in virtually all cases. Each had resections with a median of 100 percent of contrast-enhancing tumor and a median of 90 percent of non-contrast-enhancing tumor.

You Must Be Logged In To Post A Comment